VISTA and Its Ligands: the Next Generation of Promising Therapeutic Targets in Immunotherapy

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2023 Nov 8

PMID 37936192

Authors

Najibeh Shekari

Dariush Shanehbandi

Tohid Kazemi

Habib Zarredar

Behzad Baradaran

Seyed Amir Jalali

Affiliations

Soon will be listed here.

Abstract

V-domain immunoglobulin suppressor of T cell activation (VISTA) is a novel negative checkpoint receptor (NCR) primarily involved in maintaining immune tolerance. It has a role in the pathogenesis of autoimmune disorders and cancer and has shown promising results as a therapeutic target. However, there is still some ambiguity regarding the ligands of VISTA and their interactions with each other. While V-Set and Immunoglobulin domain containing 3 (VSIG-3) and P-selectin glycoprotein ligand-1(PSGL-1) have been extensively studied as ligands for VISTA, the others have received less attention. It seems that investigating VISTA ligands, reviewing their functions and roles, as well as outcomes related to their interactions, may allow an understanding of their full functionality and effects within the cell or the microenvironment. It could also help discover alternative approaches to target the VISTA pathway without causing related side effects. In this regard, we summarize current evidence about VISTA, its related ligands, their interactions and effects, as well as their preclinical and clinical targeting agents.

Citing Articles

Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy.

Almawash S Cancers (Basel). 2025; 17(5).

PMID: 40075727 PMC: 11899125. DOI: 10.3390/cancers17050880.

Chidamide functions as a VISTA/PSGL-1 blocker for cancer immunotherapy.

Niu X, Zhao W, Zhou X, Luo F, Xiao Y, Luo T Cancer Immunol Immunother. 2025; 74(3):104.

PMID: 39932560 PMC: 11813839. DOI: 10.1007/s00262-025-03955-y.

Single-cell transcriptomics unveils multifaceted immune heterogeneity in early-onset versus late-onset cervical cancer.

Chen Q, Deng D, Zhu H, Li S World J Surg Oncol. 2025; 23(1):12.

PMID: 39810181 PMC: 11730844. DOI: 10.1186/s12957-025-03654-z.

VISTA in hematological malignancies: a review of the literature.

Duan Y, Ren X, Guo X, Xie J, Liu Z, Li L Front Immunol. 2025; 15:1466839.

PMID: 39742253 PMC: 11685136. DOI: 10.3389/fimmu.2024.1466839.

Mapping the Binding Hotspots and Transient Binding Pockets on V-Domain Immunoglobulin Suppressor of T Cell Activation Protein Surface.

Li B, Xu L, Chen C, Ye J ACS Omega. 2024; 9(49):48657-48669.

PMID: 39676951 PMC: 11635502. DOI: 10.1021/acsomega.4c07757.

References

Howes J, Pugh N, Hamaia S, Jung S, Knauper V, Malcor J . MMP-13 binds to platelet receptors αIIbβ3 and GPVI and impairs aggregation and thrombus formation. Res Pract Thromb Haemost. 2018; 2(2):370-379. PMC: 5974921. DOI: 10.1002/rth2.12088. View

Deng J, Le Mercier I, Kuta A, Noelle R . A New VISTA on combination therapy for negative checkpoint regulator blockade. J Immunother Cancer. 2016; 4:86. PMC: 5168856. DOI: 10.1186/s40425-016-0190-5. View

Yasinska I, Meyer N, Schlichtner S, Hussain R, Siligardi G, Casely-Hayford M . Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity. Front Immunol. 2020; 11:580557. PMC: 7715031. DOI: 10.3389/fimmu.2020.580557. View

Mahoney K, Freeman G . Acidity changes immunology: a new VISTA pathway. Nat Immunol. 2019; 21(1):13-16. DOI: 10.1038/s41590-019-0563-2. View

Mehta N, Maddineni S, Kelly R, Lee R, Hunter S, Silberstein J . An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA. Sci Rep. 2020; 10(1):15171. PMC: 7494997. DOI: 10.1038/s41598-020-71519-4. View

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A . Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2005; 439(7077):682-7. DOI: 10.1038/nature04444. View

Ohno T, Kondo Y, Zhang C, Kang S, Azuma M . Immune Checkpoint Molecule, VISTA Regulates T-Cell-Mediated Skin Inflammatory Responses. J Invest Dermatol. 2017; 137(6):1384-1386. DOI: 10.1016/j.jid.2016.10.049. View

Green K, Wang L, Noelle R, Green W . Selective Involvement of the Checkpoint Regulator VISTA in Suppression of B-Cell, but Not T-Cell, Responsiveness by Monocytic Myeloid-Derived Suppressor Cells from Mice Infected with an Immunodeficiency-Causing Retrovirus. J Virol. 2015; 89(18):9693-8. PMC: 4542392. DOI: 10.1128/JVI.00888-15. View

Nakamura K, Smyth M . Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 2019; 17(1):1-12. PMC: 6952382. DOI: 10.1038/s41423-019-0306-1. View

10.

Kondo Y, Ohno T, Nishii N, Harada K, Yagita H, Azuma M . Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma. Oral Oncol. 2016; 57:54-60. DOI: 10.1016/j.oraloncology.2016.04.005. View

11.

Xu W, Hiu T, Malarkannan S, Wang L . The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. Cell Mol Immunol. 2018; 15(5):438-446. PMC: 6068175. DOI: 10.1038/cmi.2017.148. View

12.

Harada H, Suzu S, Hayashi Y, Okada S . BT-IgSF, a novel immunoglobulin superfamily protein, functions as a cell adhesion molecule. J Cell Physiol. 2005; 204(3):919-26. DOI: 10.1002/jcp.20361. View

13.

Watanabe T, Suda T, Tsunoda T, Uchida N, Ura K, Kato T . Identification of immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas. Cancer Sci. 2005; 96(8):498-506. PMC: 11159427. DOI: 10.1111/j.1349-7006.2005.00073.x. View

14.

Sharma S, Sundararajan A, Suryawanshi A, Kumar N, Veiga-Parga T, Kuchroo V . T cell immunoglobulin and mucin protein-3 (Tim-3)/Galectin-9 interaction regulates influenza A virus-specific humoral and CD8 T-cell responses. Proc Natl Acad Sci U S A. 2011; 108(47):19001-6. PMC: 3223445. DOI: 10.1073/pnas.1107087108. View

15.

Chen B, Zhu G, Yan A, He J, Liu Y, Li L . IGSF11 is required for pericentric heterochromatin dissociation during meiotic diplotene. PLoS Genet. 2021; 17(9):e1009778. PMC: 8448346. DOI: 10.1371/journal.pgen.1009778. View

16.

Ley K, Kansas G . Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation. Nat Rev Immunol. 2004; 4(5):325-35. DOI: 10.1038/nri1351. View

17.

Martinez M, Joffraud M, Giraud S, Baisse B, Bernimoulin M, Schapira M . Regulation of PSGL-1 interactions with L-selectin, P-selectin, and E-selectin: role of human fucosyltransferase-IV and -VII. J Biol Chem. 2004; 280(7):5378-90. DOI: 10.1074/jbc.M410899200. View

18.

ElTanbouly M, Schaafsma E, Noelle R, Lines J . VISTA: Coming of age as a multi-lineage immune checkpoint. Clin Exp Immunol. 2020; 200(2):120-130. PMC: 7160665. DOI: 10.1111/cei.13415. View

19.

Li X, Zhang X, Li Z, Yang Y, Zhang D, Zheng H . Effect of Matrix Metallopeptidase 13 on the Function of Mouse Bone Marrow-derived Dendritic Cells. Chin Med J (Engl). 2017; 130(6):717-721. PMC: 5358423. DOI: 10.4103/0366-6999.201602. View

20.

Xie X, Chen C, Chen W, Jiang J, Wang L, Li T . Structural Basis of VSIG3: The Ligand for VISTA. Front Immunol. 2021; 12:625808. PMC: 8027081. DOI: 10.3389/fimmu.2021.625808. View